Oncolytics Biotech Inc. (ONCY)
$2.13
-0.03 (-1.39%)
Rating:
Recommendation:
-
| Symbol | ONCY |
|---|---|
| Price | $2.13 |
| Beta | 1.739 |
| Volume Avg. | 0.84M |
| Market Cap | 156.276M |
| Shares () | - |
| 52 Week Range | 1.09-3.39 |
| 1y Target Est | - |
| DCF Unlevered | ONCY DCF -> | |
|---|---|---|
| DCF Levered | ONCY LDCF -> | |
| ROE | -103.07% | Strong Sell |
| ROA | -82.93% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 2.15% | Neutral |
| P/E | -6.66 | Strong Sell |
| P/B | 8.33 | Strong Buy |
Latest ONCY news
About
Download (Excel)Dr. Matthew C. Coffey M.B.A., Ph.D.
Healthcare
Biotechnology
NASDAQ Capital Market
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.